Acetyl-CDKN1C (K278) Antibody

What is CDKN1C and why is the acetylation at K278 significant?

CDKN1C (cyclin-dependent kinase inhibitor 1C), also known as p57KIP2, is a key cell cycle regulator belonging to the Cip/Kip family of CDK inhibitors. The protein functions primarily by binding to and inhibiting several cyclin/CDK complexes, thereby negatively regulating cell proliferation and contributing to cell cycle arrest at G1 phase.

The acetylation at lysine 278 (K278) represents an important post-translational modification that can significantly alter CDKN1C's functionality. This specific modification affects protein-protein interactions, subcellular localization, and potentially the protein's stability. When studying cell cycle regulation mechanisms, the ability to detect this specific acetylation site provides valuable insights into how post-translational modifications modulate CDKN1C's inhibitory functions in different cellular contexts .

How does Acetyl-CDKN1C (K278) Antibody differ from non-acetylation specific CDKN1C antibodies?

The key differentiating factor is epitope specificity. The Acetyl-CDKN1C (K278) Antibody specifically recognizes the acetylated lysine at position 278 of human p57 protein, making it suitable for studying this particular post-translational modification. This contrasts with standard CDKN1C antibodies that may recognize the protein regardless of its acetylation status .

Non-acetylation specific antibodies, such as the one described in search result , target different regions of CDKN1C (like the AA range 241-290) but are not sensitive to the acetylation state. This distinction is crucial when designing experiments to investigate the specific role of K278 acetylation in various cellular processes .

The immunogen used for generating the Acetyl-CDKN1C (K278) Antibody is a synthesized peptide derived from human p57 specifically surrounding the acetylation site at K278, ensuring high specificity for this modified form of the protein .

What are the recommended applications for Acetyl-CDKN1C (K278) Antibody?

Based on manufacturer validations, Acetyl-CDKN1C (K278) Antibody is suitable for:

• Western Blot (WB): The antibody can detect the acetylated form of CDKN1C in protein lysates, with recommended dilutions typically in the range of 1:500-1:2000 .

• ELISA (Enzyme-Linked Immunosorbent Assay): Enables quantitative detection of acetylated CDKN1C in various sample types .

While these are the validated applications, researchers should consider that other CDKN1C antibodies have been successfully used in additional techniques such as:

• Immunohistochemistry (IHC)

• Immunofluorescence (IF)

• Flow Cytometry (FCM)

When adapting the Acetyl-CDKN1C (K278) Antibody for applications beyond those validated by the manufacturer, appropriate optimization and validation steps should be performed to ensure specificity and sensitivity in the new context.

How can Acetyl-CDKN1C (K278) Antibody be used to investigate cellular stress response mechanisms?

Investigating cellular stress response using this antibody requires an integrated experimental approach:

• Stress Induction Protocol Design: Establish models exposing cells to various stressors (oxidative stress, DNA damage, metabolic stress) with appropriate time courses.

• Comparative Analysis Framework: Design experiments that assess both total CDKN1C levels (using a non-acetylation specific antibody) and acetylated CDKN1C at K278 simultaneously across treatment conditions.

• Temporal Profiling: Monitor acetylation changes at K278 over a time course following stress induction, which often reveals dynamic regulation patterns.

• Co-localization Studies: Combine the Acetyl-CDKN1C (K278) Antibody with markers for subcellular compartments to track stress-induced relocalization.

• Enzyme Inhibition Approaches: Use histone deacetylase (HDAC) inhibitors or acetylase inhibitors alongside stress treatments to determine which enzymes regulate K278 acetylation under stress conditions.

The appropriate dilution ratio for Western blot applications (1:500-1:2000) should be optimized based on your specific cellular model and stress conditions . This methodological framework allows researchers to establish connections between specific stressors and CDKN1C acetylation dynamics, potentially revealing novel regulatory mechanisms.

What controls are essential when studying CDKN1C acetylation patterns?

A robust experimental design for studying CDKN1C acetylation should include:

Positive Controls:

• Lysates from cells treated with HDAC inhibitors (e.g., trichostatin A or sodium butyrate) to increase global protein acetylation

• Recombinant acetylated CDKN1C protein (if available)

• Cell lines known to express high levels of acetylated CDKN1C

Negative Controls:

• CDKN1C knockout/knockdown samples

• Samples treated with deacetylase enzymes

• Peptide competition assays using the acetylated immunogen peptide

Technical Controls:

• Parallel blots with antibodies targeting total CDKN1C to normalize acetylation levels

• Loading controls (e.g., β-actin, GAPDH) to ensure equal protein loading

• Use of both acetylation-specific and non-acetylation specific CDKN1C antibodies on the same samples for comparison

Validation Controls:

• Immunoprecipitation followed by mass spectrometry to confirm the presence of acetylation at K278

• Site-directed mutagenesis of K278 to arginine (K278R) to create an acetylation-deficient mutant

The inclusion of these controls helps validate the specificity of the observed signals and ensures that experimental observations truly reflect changes in CDKN1C acetylation rather than artifacts or non-specific binding.

What is the optimal protocol for using Acetyl-CDKN1C (K278) Antibody in Western Blot applications?

Optimized Western Blot Protocol for Acetyl-CDKN1C (K278) Detection:

Sample Preparation:

• Harvest cells during appropriate cell cycle phase (G1 arrest typically shows highest CDKN1C expression)

• Lyse cells in buffer containing deacetylase inhibitors (e.g., 5-10 mM nicotinamide, 1 μM trichostatin A)

• Clear lysates by centrifugation (14,000 g, 15 min, 4°C)

• Determine protein concentration (BCA or Bradford assay)

Gel Electrophoresis and Transfer:

• Load 20-50 μg protein per lane on 10-12% SDS-PAGE gels

• Include molecular weight markers covering the 30-40 kDa range

• Transfer to PVDF membrane (recommended over nitrocellulose for acetylated proteins)

• Confirm transfer efficiency with reversible staining (Ponceau S)

Antibody Incubation:

• Block membrane in 5% BSA in TBST (not milk, which contains deacetylases)

• Incubate with Acetyl-CDKN1C (K278) Antibody at 1:1000 dilution in 5% BSA/TBST overnight at 4°C

• Wash 3× with TBST, 10 minutes each

• Incubate with HRP-conjugated secondary antibody (anti-rabbit) at 1:5000 in 5% BSA/TBST for 1 hour at room temperature

• Wash 3× with TBST, 10 minutes each

Detection and Analysis:

• Develop using enhanced chemiluminescence (ECL) substrate

• Expected band at approximately 39 kDa (observed) or 32.2 kDa (calculated)

• Quantify signal relative to total CDKN1C and loading controls

Troubleshooting Notes:

• If non-specific bands appear, increase blocking time and antibody dilution

• If signal is weak, reduce antibody dilution to 1:500 and extend exposure time

• The observed molecular weight (39 kDa) may differ from the calculated weight (32.2 kDa) due to post-translational modifications

How should samples be prepared to preserve acetylation status for Acetyl-CDKN1C (K278) detection?

Preserving acetylation status during sample preparation is critical for accurate detection with Acetyl-CDKN1C (K278) Antibody:

Cell/Tissue Harvesting:

• Process samples rapidly to minimize enzymatic deacetylation

• When possible, treat live cells with membrane-permeable deacetylase inhibitors (1 μM TSA, 5 mM nicotinamide) 30 minutes before harvesting

Lysis Buffer Composition:

• Base buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40 or Triton X-100

• Deacetylase inhibitors: 5-10 mM nicotinamide, 1 μM trichostatin A, 10 mM sodium butyrate

• Protease inhibitors: Complete protease inhibitor cocktail

• Phosphatase inhibitors: 1 mM sodium orthovanadate, 10 mM sodium fluoride

Storage Conditions:

• Aliquot lysates to minimize freeze-thaw cycles

• Store at -80°C for long-term storage

• Add fresh deacetylase inhibitors when thawing samples

Sample Handling During Experimentation:

• Keep samples on ice at all times

• Add deacetylase inhibitors to all buffers used in immunoprecipitation procedures

• Avoid detergents that may preferentially solubilize non-acetylated forms of the protein

This careful approach to sample preparation ensures that the acetylation state of CDKN1C is maintained throughout experimental procedures, allowing for reliable detection of the acetylated K278 site .

How do you interpret discrepancies between observed (39 kDa) and calculated (32.2 kDa) molecular weights of CDKN1C?

The discrepancy between the observed molecular weight (39 kDa) and calculated molecular weight (32.2 kDa) of CDKN1C is a common phenomenon that requires careful interpretation:

Causes of Higher Apparent Molecular Weight:

Interpretation Guidelines:

• Confirmation of Identity:

  • Perform peptide competition assays with the immunizing peptide

  • Use CDKN1C knockout/knockdown controls to verify band specificity

  • Compare migration patterns with other validated CDKN1C antibodies

• Analysis of Modifications:

  • Treat samples with phosphatases, deacetylases, or deglycosylation enzymes to determine if modifications contribute to the observed weight

  • Compare migration patterns across different tissue/cell types that may have different CDKN1C modification profiles

• Technical Verification:

  • Run gradient gels to better resolve the protein

  • Use alternative molecular weight markers

  • Employ different electrophoresis buffer systems

The 7 kDa difference observed with CDKN1C is consistent with the presence of multiple post-translational modifications, which are known to regulate CDKN1C function in different cellular contexts. Rather than indicating an experimental problem, this discrepancy likely reflects biologically relevant modifications of the protein .

What strategies can resolve weak or inconsistent signals when using Acetyl-CDKN1C (K278) Antibody?

When encountering weak or inconsistent signals with Acetyl-CDKN1C (K278) Antibody, implement this structured troubleshooting approach:

Signal Enhancement Strategies:

• Sample Preparation Optimization:

  • Increase deacetylase inhibitor concentrations in lysis buffer

  • Enrich acetylated proteins using anti-acetyllysine antibody immunoprecipitation before Western blot

  • Use fresh samples whenever possible, as acetylation can be lost during storage

• Protocol Adjustments:

  • Decrease antibody dilution (try 1:500 if using 1:1000)

  • Extend primary antibody incubation to overnight at 4°C

  • Switch membrane type (PVDF often retains acetylated proteins better than nitrocellulose)

  • Increase protein loading (up to 50-75 μg per lane)

  • Use a more sensitive detection system (e.g., SuperSignal West Femto)

• Biological Considerations:

  • Verify CDKN1C expression levels in your cell type or tissue

  • Consider cell cycle synchronization to maximize CDKN1C expression

  • Treat cells with HDAC inhibitors to increase global acetylation

Consistency Improvement Measures:

• Standardize Sample Handling:

  • Establish a consistent time between harvest and lysis

  • Standardize freeze-thaw cycles

  • Use consistent protein quantification methods

• Technical Standardization:

  • Use the same gel system and transfer conditions

  • Prepare fresh transfer buffer for each experiment

  • Standardize incubation times and temperatures

• Controls Implementation:

  • Run positive control samples (HDAC inhibitor-treated cells) on each blot

  • Use internal reference standards across blots

  • Implement technical replicates within experiments

When implemented systematically, these approaches can significantly improve signal quality and consistency when working with the acetylation-specific Acetyl-CDKN1C (K278) Antibody .

How can Acetyl-CDKN1C (K278) Antibody be used to investigate cross-talk between acetylation and other post-translational modifications?

Investigating PTM cross-talk requires sophisticated experimental design:

• Sequential Immunoprecipitation Approach:

  • First IP: Use Acetyl-CDKN1C (K278) Antibody to isolate acetylated CDKN1C

  • Secondary analysis: Probe with antibodies against other PTMs (phosphorylation, ubiquitination)

  • Alternative: Reverse the order to determine if other PTMs precede or follow acetylation

• Mass Spectrometry Integration:

  • Immunoprecipitate with Acetyl-CDKN1C (K278) Antibody

  • Analyze by LC-MS/MS to identify co-occurring modifications

  • Create a modification map showing relationships between K278 acetylation and other PTMs

• Enzyme Modulation Studies:

  • Treat cells with combinations of enzyme inhibitors targeting different modifications

  • Example experimental design:

    Treatment Group	HDAC Inhibitor	Kinase Inhibitor	Proteasome Inhibitor	Expected Outcome
    Control	No	No	No	Baseline PTM pattern
    Acetylation enhanced	Yes	No	No	Increased K278 acetylation
    Phosphorylation inhibited	No	Yes	No	Effect on K278 acetylation?
    Combined modulation	Yes	Yes	No	Synergistic/antagonistic effects?
    Degradation inhibited	No	No	Yes	Accumulation of modified forms

• Temporal Dynamics Analysis:

  • Time-course experiments following stimulation

  • Compare appearance/disappearance rates of different PTMs

  • Establish cause-effect relationships between modifications

This multi-faceted approach can reveal whether K278 acetylation is dependent on, or a prerequisite for, other modifications, deepening our understanding of CDKN1C regulation .

What are the considerations when using Acetyl-CDKN1C (K278) Antibody across different species?

The Acetyl-CDKN1C (K278) Antibody shows reactivity to human, mouse, and rat samples, but cross-species applications require careful consideration:

Sequence Conservation Analysis:

Cross-Species Validation Steps:

• Preliminary Assays:

  • Run Western blots with positive controls from each species

  • Compare band intensities and molecular weights

  • Verify specificity with blocking peptides

• Concentration Adjustments:

  • May require higher antibody concentrations for less conserved species

  • Recommended starting dilution for non-validated species: 1:500

• Alternative Detection Methods:

  • Consider more sensitive detection systems for weakly cross-reactive species

  • Longer exposure times may be necessary

• Controls for Non-validated Species:

  • Include acetylation-inducing treatments as positive controls

  • Run parallel blots with species-specific total CDKN1C antibodies

  • Consider acetylation site-specific mutants if available

When working with species beyond human, mouse, and rat, preliminary validation experiments are essential to confirm antibody performance and optimize conditions for reliable detection of acetylated CDKN1C .

How can Acetyl-CDKN1C (K278) detection be integrated into multi-omics research approaches?

Integrating Acetyl-CDKN1C (K278) analysis into multi-omics research requires strategic experimental design:

• Proteomics Integration:

  • Parallel analysis of total proteome, acetylome, and CDKN1C interactome

  • Correlation between K278 acetylation and global acetylation patterns

  • Network analysis to identify functional connections

• Transcriptomics Correlation:

  • RNA-seq to identify genes whose expression correlates with CDKN1C K278 acetylation status

  • ChIP-seq with Acetyl-CDKN1C (K278) Antibody to identify genomic binding sites

  • Integration of expression data with CDKN1C binding patterns

• Metabolomics Connections:

  • Analyze metabolic changes associated with altered CDKN1C acetylation

  • Focus on acetyl-CoA metabolism as the acetyl donor for protein acetylation

  • Investigate NAD+ metabolism affecting SIRT-family deacetylases

• Data Integration Framework:

  Omics Layer	Technology	Connection to CDKN1C Acetylation	Analysis Approach
  Genomics	WGS/WES	Genetic variants affecting acetylation	Variant annotation, regulatory element analysis
  Transcriptomics	RNA-seq	Expression changes correlated with acetylation	Differential expression, co-expression networks
  Proteomics	MS/WB	Direct measurement of K278 acetylation	PTM site mapping, quantitative analysis
  Acetylomics	Acetyl-enriched MS	Global acetylation patterns	Pathway enrichment of acetylated proteins
  Interactomics	IP-MS with acetyl-specific antibody	Differential interactions based on acetylation	Protein-protein interaction networks
  Metabolomics	LC-MS	Metabolites affecting acetylation machinery	Pathway analysis, metabolite set enrichment

• Computational Integration:

  • Machine learning approaches to identify patterns across omics layers

  • Causal network modeling to establish regulatory relationships

  • Visualization of multi-dimensional data centered on CDKN1C acetylation

This integrative approach provides a comprehensive understanding of how K278 acetylation of CDKN1C fits into broader cellular regulatory networks .

What are the methodological considerations for studying CDKN1C acetylation in patient-derived samples?

Working with patient-derived samples requires specialized protocols to maintain acetylation status and account for sample variability:

Sample Collection and Processing:

• Timing Considerations:

  • Minimize time between sample collection and processing

  • Document ischemia time as it affects acetylation patterns

  • Process samples within 30 minutes when possible

• Preservation Methods:

  • Flash-freezing in liquid nitrogen preferred for acetylation studies

  • For FFPE samples, use acetylation-preserving fixation protocols:

    • Short fixation times (≤24 hours)

    • Buffered formalin pH 7.0-7.4

    • Cold fixation (4°C) when possible

• Storage Protocols:

  • Store at -80°C with minimal freeze-thaw cycles

  • Document storage duration for all samples

  • Consider vacuum-sealed storage to prevent oxidation

Analytical Considerations:

• Extraction Optimization:

  • Buffer composition must include deacetylase inhibitors at higher concentrations than cell lines

  • Additional protease inhibitors to counter elevated proteolytic activity

  • Techniques to overcome extracellular matrix interference

• Normalization Strategies:

  • Use multiple housekeeping proteins as references

  • Consider tissue-specific internal controls

  • Normalize acetylated CDKN1C to total CDKN1C levels

• Heterogeneity Management:

  • Microdissection for enrichment of specific cell types

  • Single-cell approaches when feasible

  • Histological verification of sample composition

Clinical Correlation Framework:

• Clinical Data Integration:

  • Standardized collection of relevant clinical parameters

  • Statistical approaches accounting for confounding variables

  • Multivariate analysis correlating acetylation with clinical outcomes

• Experimental Design:

  • Include appropriate healthy controls matched for age/sex

  • Account for medication effects on acetylation machinery

  • Consider disease-specific factors affecting global acetylation

This methodological framework ensures reliable detection of CDKN1C acetylation in patient samples while accounting for the inherent challenges of clinical specimens .